Brief: Eterna Therapeutics Completes Name Change, Acquires Option To License Nk And T Cell Therapies From Exacis Biotherapeutics

Ernexa Therapeutics

17/10/2022 13:59

Oct 17 (Reuters) - Brooklyn Immunotherapeutics Inc
 ERNA.O :
    * ETERNA THERAPEUTICS COMPLETES NAME CHANGE, ACQUIRES OPTION
TO
LICENSE IPSC-DERIVED NK AND T CELL THERAPIES FROM EXACIS
BIOTHERAPEUTICS

Source text for Eikon:  ID:nGNX1QsRnH 
Further company coverage:  ERNA.O 
 ((Reuters.Briefs@thomsonreuters.com;))